Vendor, Kansas City, MO
Dclk1 LLC
UEI J7NHEJ9JFXD5, CAGE 80EU9
1 award and $0 obligated between January 26, 2024 and June 14, 2024, 100% under full and open competition, against 17.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91023C00008Definitive Contract, January 26, 2024, Full and Open Competition After Exclusion of Sources, 17 offers | NIH NCINational Institutes of Health | SBIR Concept Award-Nanosponge Linked Dclk1 Inhibitors for the Targeted Treatment of CholangiocarcinomaNAICS 541714, PSC AN12 | $0 |
- Places of performance
- Missouri
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 2 across 1 awards